Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain

References

• Ryder S, Fox K, Rane P, et al. A systematic review of direct cardiovascular event costs: an international perspective. Pharmacoeconomics. 2019;37(7):895–919. doi:10.1007/s40273-019-00795-430949988
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3):293–301. doi:10.1016/j.diabres.2010.01.02620171754
   PubMed Web of Science ®Google Scholar
• Bresee LC, Majumdar SR, Patten SB, Johnson JA. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res. 2010;117(1):75–82. doi:10.1016/j.schres.2009.12.01620080392
   PubMed Web of Science ®Google Scholar
• Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–180. doi:10.1002/wps.2042028498599
   PubMed Web of Science ®Google Scholar
• Kelly DL, McMahon RP, Liu F, et al. Cardiovascular disease mortality in chronic schizophrenia patients treated with clozapine. J Clin Psychiatry. 2010;71(3):304. doi:10.4088/JCP.08m04718yel20079332
   PubMed Web of Science ®Google Scholar
• Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77. doi:10.1016/S2215-0366(19)30416-X31860457
   PubMed Web of Science ®Google Scholar
• Keating D, McWilliams S, Schneider I, et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open. 2017;7(1):e013881. doi:10.1136/bmjopen-2016-013881
   PubMed Web of Science ®Google Scholar
• Millier A, Zineddine O, Zhou J, Aballea S, Taieb V, Toumi M. A network meta-analysis to compare the efficacy and safety of antipsychotics as maintenance treatment for patients with schizophrenia. Value Health. 2017;20(9):A709. doi:10.1016/j.jval.2017.08.1866
   Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. doi:10.1016/S0140-6736(19)31135-331303314
   PubMed Web of Science ®Google Scholar
• Mehnert A, Nicholl D, Pudas H, Martin M, McGuire A. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J Med Econ. 2012;15(5):844–861. doi:10.3111/13696998.2012.68153122458756
   PubMedGoogle Scholar
• Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry. 2008;7:16. doi:10.1186/1744-859X-7-1618755025
   PubMedGoogle Scholar
• Davies A, Vardeva K, Loze JY, G J L, Sennfalt K, Baardewijk M. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK. Curr Med Res Opin. 2008;24(11):3275–3285. doi:10.1185/0300799080250754718947458
   PubMed Web of Science ®Google Scholar
• Treur M, Baca E, Bobes J, et al. The cost-effectiveness of paliperidone extended release in Spain. J Med Econ. 2012;15(Suppl 1):26–34. doi:10.3111/13696998.2012.73488423016569
   PubMedGoogle Scholar
• O’Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. Clinicoecon Outcomes Res. 2013;5:459–470. doi:10.2147/CEOR.S4799024049452
   PubMedGoogle Scholar
• Garcia-Ruiz AJ, Perez-Costillas L, Montesinos AC, Alcalde J, Oyaguez I, Casado MA. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Econ Rev. 2012;2(1):8. doi:10.1186/2191-1991-2-822828390
   PubMedGoogle Scholar
• Citrome L, Kamat SA, Sapin C, et al. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. J Med Econ. 2014;17(8):567–576. doi:10.3111/13696998.2014.91708924758296
   PubMedGoogle Scholar
• Obradovic M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract. 2007;61(12):1979–1988. doi:10.1111/j.1742-1241.2007.01431.x17997804
   PubMed Web of Science ®Google Scholar
• Excellence N. Psychosis and schizophrenia in adults: prevention and management. NICE Guidelines. 2014.
   Google Scholar
• Lindstrom E, Eberhard J, Fors BM, Hansen K, Sapin C. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nord J Psychiatry. 2011;65(6):403–413. doi:10.3109/08039488.2011.59060321770821
   PubMed Web of Science ®Google Scholar
• Marazuela R, Rubio-Terrés C, Giner J, Jiménez FJ. Pharmacoeconomic analysis of the treatment of schizophrenia with quetiapine, olanzapine, risperidone or haloperidol in Spain. J Med Econ. 2008;9(1–4):101–119. doi:10.3111/200609101119
   Google Scholar
• Kasteng F, Eriksson J, Sennfalt K, Lindgren P. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2011;124(3):214–225. doi:10.1111/j.1600-0447.2011.01716.x21609324
   PubMed Web of Science ®Google Scholar
• Correll CU, Davis RE, Weingart M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(4):349. doi:10.1001/jamapsychiatry.2019.437931913424
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Davis RE, Correll CU, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016;79(12):952–961. doi:10.1016/j.biopsych.2015.08.02626444072
   PubMed Web of Science ®Google Scholar
• Durgam S, Earley W, Li R, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016;176(2–3):264–271. doi:10.1016/j.schres.2016.06.03027427558
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Hobart M, Ouyang J, et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2017;20(1):11–21. doi:10.1093/ijnp/pyw07627566723
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study. BMJ. 2017;359:j5019. doi:10.1136/bmj.j501929158232
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099. doi:10.1136/bmj.j209928536104
   PubMed Web of Science ®Google Scholar
• Zomer E, Osborn D, Nazareth I, et al. Effectiveness and cost-effectiveness of a cardiovascular risk prediction algorithm for people with severe mental illness (PRIMROSE). BMJ Open. 2017;7(9):e018181. doi:10.1136/bmjopen-2017-018181
   PubMed Web of Science ®Google Scholar
• Barnett AH, Millar HL, Loze JY, L’Italien GJ, van Baardewijk M, Knapp M. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). Eur Arch Psychiatry Clin Neurosci. 2009;259(4):239–247. doi:10.1007/s00406-008-0863-219267255
   PubMed Web of Science ®Google Scholar
• Nerat T, Kos M. Burden of type 2 diabetes from the healthcare payer perspective in Slovenia/Breme Sladkorne Bolezni Tipa 2 S Stališča Plačnika Zdravstvenega Varstva V Sloveniji. SJPH. 2013;52(3):162–180. doi:10.2478/sjph-2013-0018
   Web of Science ®Google Scholar
• Reuters. BRIEF-intra-cellular says wholesale acquisition price for caplyta is $1,320/month. 2020 Available from: https://www.reuters.com/article/brief-intra-cellular-says-wholesale-acqu/brief-intra-cellular-says-wholesale-acquisition-price-for-caplyta-is-1320-month-idUSFWN2BG0N6. Accessed 17, 2021.
   Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force–3. Med Decis Making. 2012;32(5):690–700. doi:10.1177/0272989X1245546322990084
   PubMed Web of Science ®Google Scholar
• Németh B, Bendes R, Nagy B, et al. Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia. Health Policy Technol. 2019;8(1):84–91. doi:10.1016/j.hlpt.2019.01.004
   Web of Science ®Google Scholar
• Rajagopalan K, Trueman D, Crowe L, Squirrell D, Loebel A. Cost-utility analysis of lurasidone versus aripiprazole in adults with schizophrenia. Pharmacoeconomics. 2016;34(7):709–721. doi:10.1007/s40273-016-0405-027067724
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123–1131. doi:10.1001/archpsyc.64.10.112317909124
   PubMed Web of Science ®Google Scholar
• Hong J, Windmeijer F, Novick D, Haro JM, Brown J. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(5):835–841. doi:10.1016/j.pnpbp.2009.03.03419351551
   PubMed Web of Science ®Google Scholar
• Arteaga Duarte C, Colin X, De Moor R, Guillon P, van Gils CW. Three-monthly long-acting formulation of paliperidone palmitate is a dominant treatment option, cost saving while adding qalys, compared to the one-monthly formulation in the treatment of schizophrenia in France. Value Health. 2016;19(7):A378. doi:10.1016/j.jval.2016.09.181
   Web of Science ®Google Scholar
• Colombo GL, Caruggi M, Di Matteo S, Rossi A. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat. 2008;4(5):967. doi:10.2147/NDT.S370119183788
   PubMedGoogle Scholar
• Eurostat. Cardiovascular diseases statistics. Published 2020 Available from: https://ec.europa.eu/eurostat/statistics-explained/index.php/Cardiovascular_diseases_statistics. Accessed 17, 2021.
   Google Scholar
• Druais S, Doutriaux A, Cognet M, et al. Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in France. Pharmacoeconomics. 2016;34(4):363–391. doi:10.1007/s40273-015-0348-x26883132
   PubMed Web of Science ®Google Scholar
• Zhao YJ, Lin L, Teng M, et al. Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. BJPsych Open. 2016;2(1):59–66. doi:10.1192/bjpo.bp.115.00257627703755
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Y, Su Y, et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017;17(1):373. doi:10.1186/s12888-017-1539-029162032
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019;18(2):208–224. doi:10.1002/wps.2063231059621
   PubMed Web of Science ®Google Scholar
• Kishi T, Ikuta T, Matsuda Y, Sakuma K, Iwata N. Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. Psychopharmacology. 2020;30:30.
   Google Scholar
• Kishi T, Ikuta T, Matsunaga S, Matsuda Y, Oya K, Iwata N. Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population. Neuropsychiatr Dis Treat. 2017;13:1281–1302. doi:10.2147/NDT.S13434028553116
   PubMed Web of Science ®Google Scholar
• Maman K, Krause T, Pedersen AM, et al. Pmh4 an indirect treatment comparison of brexpiprazole versus lurasidone in patients undergoing acute and maintenance phase treatment for schizophrenia. Value Health. 2019;22(Supplement 2):S226. doi:10.1016/j.jval.2019.04.1050
   Web of Science ®Google Scholar
• Zhu Y, Krause M, Huhn M, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry. 2017;4(9):694–705. doi:10.1016/S2215-0366(17)30270-528736102
   PubMed Web of Science ®Google Scholar
• Ng-Mak D, Tongbram V, Ndirangu K, Rajagopalan K, Loebel A. Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis. J Comp Eff Res. 2018;7(8):737–748. doi:10.2217/cer-2018-001629697278
   PubMed Web of Science ®Google Scholar
• Kishi T, Oya K, Matsui Y, et al. Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials. Neuropsychiatr Dis Treat. 2018;14:2519–2530. doi:10.2147/NDT.S17667630319261
   PubMed Web of Science ®Google Scholar
• Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927–942. doi:10.1176/appi.ajp.2017.1612135828541090
   PubMed Web of Science ®Google Scholar
• Zhao MJ, Qin B, Wang JB, et al. Efficacy and acceptability of cariprazine in acute exacerbation of schizophrenia: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol. 2018;38(1):55–59. doi:10.1097/JCP.000000000000083429257786
   PubMed Web of Science ®Google Scholar
• Zheng W, Cai DB, Yang XH, et al. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: a meta-analysis of randomized controlled trials. J Psychiatr Res. 2018;103:244–251. doi:10.1016/j.jpsychires.2018.06.00529906709
   PubMed Web of Science ®Google Scholar
• Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;11:CD006625.
   PubMed Web of Science ®Google Scholar
• Hutton P, Taylor PJ, Mulligan L, Tully S, Moncrieff J. Quetiapine immediate release v. placebo for schizophrenia: systematic review, meta-analysis and reappraisal. Br J Psychiatry. 2015;206(5):360–370. doi:10.1192/bjp.bp.114.15437725934300
   PubMed Web of Science ®Google Scholar
• Marder SR, Hakala MJ, Josiassen MK, et al. Brexpiprazole in patients with schizophrenia: overview of short-and long-Term Phase 3 controlled studies. Acta Neuropsychiatr. 2017;29(5):278–290. doi:10.1017/neu.2016.5727846922
   PubMed Web of Science ®Google Scholar
• Rattehalli RD, Zhao S, Li BG, Jayaram MB, Xia J, Sampson S. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev. 2016;12:CD006918.27977041
   PubMed Web of Science ®Google Scholar
• Nussbaum A, Stroup TS. Paliperidone for schizophrenia. Cochrane Database Syst Rev. 2008;(2):CD006369.18425951
   PubMed Web of Science ®Google Scholar
• Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016;73(3):199–210. doi:10.1001/jamapsychiatry.2015.295526842482
   PubMed Web of Science ®Google Scholar
• Cortesi PA, Mencacci C, Luigi F, et al. Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. BMC Psychiatry. 2013;13(1):98. doi:10.1186/1471-244X-13-9823522406
   PubMed Web of Science ®Google Scholar
• Fefeu M, De Maricourt P, Cachia A, et al. One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia. Psychiatry Res. 2018;270:205–210. doi:10.1016/j.psychres.2018.09.04130267984
   PubMed Web of Science ®Google Scholar
• Hodgson RE. Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting. Clinicoecon Outcomes Res. 2019;11:517–524. doi:10.2147/CEOR.S19119831616168
   PubMed Web of Science ®Google Scholar
• Dernovsek M, Rupel VP, Rebolj M, Tavcar R. Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics. Eur Psychiatry. 2001;16(8):474–482. doi:10.1016/S0924-9338(01)00609-511777738
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Maurino J, Ruiz-Beato E, Navarro-Artieda R. Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study. BMC Psychiatry. 2014;14(1):225. doi:10.1186/s12888-014-0225-825096022
   PubMed Web of Science ®Google Scholar
• Exchange GHD. GBD results tool. Institute for Health Metrics and Evaluation Seattle; 2019 Available from: http://ghdx.healthdata.org/gbd-results-tool. Accessed 17, 2021.
   Google Scholar
• OECD. Health risks - Daily smokers - OECD data. 2020 Available from: https://data.oecd.org/healthrisk/daily-smokers.htm. Accessed 17, 2021.
   Google Scholar
• Bank W. GDP deflator. 2018 Available from: https://data.worldbank.org/indicator/NY.GDP.DEFL.ZS. Accessed 17, 2021.
   Google Scholar
• OECD. Purchasing power parities. 2020 Available from: https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm. Accessed 17, 2021.
   Google Scholar
• de Arce Cordón R, Eding E, Marques-Teixeira J, Milanova V, Rancans E, Schreiner A. Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Eur Arch Psychiatry Clin Neurosci. 2012;262(2):139–149. doi:10.1007/s00406-011-0220-821809168
   PubMed Web of Science ®Google Scholar
• Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367–2377. doi:10.1038/npp.2010.11120686456
   PubMed Web of Science ®Google Scholar
• Addington DE, Labelle A, Kulkarni J, Johnson G, Loebel A, Mandel FS. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. Can J Psychiatry. 2009;54(1):46–54. doi:10.1177/07067437090540010819175979
   PubMed Web of Science ®Google Scholar
• Meyer JM, Mao Y, Pikalov A, Cucchiaro J, Loebel A. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. Int Clin Psychopharmacol. 2015;30(6):342. doi:10.1097/YIC.000000000000009126196189
   PubMed Web of Science ®Google Scholar
• Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006;27(13):1610–1619. doi:10.1093/eurheartj/ehi73316495286
   PubMed Web of Science ®Google Scholar
• Ray JA, Valentine WJ, Secnik K, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin. 2005;21(10):1617–1629. doi:10.1185/030079905X6534916238902
   PubMed Web of Science ®Google Scholar
• Ekman M. Economic evidence in stroke: a review. Eur J Health Econ. 2004;5:S74. doi:10.1007/s10198-005-0292-315754078
   PubMedGoogle Scholar
• Truelsen T, Ekman M, Boysen G. Cost of stroke in Europe. Eur J Neurol. 2005;12:78–84. doi:10.1111/j.1468-1331.2005.01199.x15877785
   PubMed Web of Science ®Google Scholar
• Lamotte M, Annemans L, Evers T, Kubin M. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics. 2006;24(2):155–169. doi:10.2165/00019053-200624020-0000516460136
   PubMed Web of Science ®Google Scholar
• Brodszky V, Beretzky Z, Baji P, et al. Cost-of-illness studies in nine Central and Eastern European countries. Eur J Health Econ. 2019;20(Suppl 1):155–172. doi:10.1007/s10198-019-01066-x31104219
   PubMed Web of Science ®Google Scholar
• Terent A, Marke L-A, Asplund K, Norrving B, Jonsson E, Wester P-O. Costs of stroke in Sweden. A national perspective. Stroke. 1994;25(12):2363–2369. doi:10.1161/01.STR.25.12.23637974574
   PubMed Web of Science ®Google Scholar
• Kanavos P, van den Aardweg S, Schurer W. Diabetes expenditure, burden of disease and management in 5 EU countries. LSE Health Social Care. 2012.
   Google Scholar
• Jönsson B. Revealing the cost of type II diabetes in Europe. Diabetologia. 2002;45(1):S5–S12. doi:10.1007/s00125-002-0858-x
   Web of Science ®Google Scholar
• Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health. 2004;7(5):569–584. doi:10.1111/j.1524-4733.2004.75008.x15367252
   PubMed Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc. 2009;7:4. doi:10.1186/1478-7547-7-419351408
   PubMedGoogle Scholar
• Oxford Health NHS Foundation Trust. Antipsychotic-induced hyperprolactinaemia - Trust guideline for identification, monitoring and management. 2015 Available from: http://www.oxfordhealthformulary.nhs.uk/docs/AntipsychoticinducedhyperprolactinaemiaguidelineJuly2015.pdf. Accessed 17, 2021.
   Google Scholar
• Grigg J, Worsley R, Thew C, Gurvich C, Thomas N, Kulkarni J. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology. 2017;234(22):3279–3297. doi:10.1007/s00213-017-4730-628889207
   PubMed Web of Science ®Google Scholar
• Dilla T, O’Donohoe P, Moller J, et al. Cost-effectiveness of long-acting olanzapine versus long-acting risperidone in patients with schizophrenia in Spain. Value Health. 2011;14(7):A292. doi:10.1016/j.jval.2011.08.331
   Web of Science ®Google Scholar
• Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184(4):346–351. doi:10.1192/bjp.184.4.34615056580
   PubMed Web of Science ®Google Scholar
• Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess. 2003;7(13). doi:10.3310/hta7130.
   Google Scholar
• Tilden D, Aristides M, Meddis D, Burns T. An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. Clin Ther. 2002;24(10):1648–1667. doi:10.1016/S0149-2918(02)80069-812462294
   PubMed Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071. doi:10.1016/S0140-6736(12)60239-622560607
   PubMed Web of Science ®Google Scholar
• World Health Organisation. ATC/DDD Index 2020. 2020 Available from: https://www.whocc.no/atc_ddd_index/. Accessed 17, 2021.
   Google Scholar
• Committee JF. British national formulary (BNF) 66: aripiprazole. Vol 66. Pharmaceutical Press; 2013 Available from: https://bnf.nice.org.uk/drug/aripiprazole.html. Accessed 17, 2021.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS med 2009. Jul 21;6(7):e1000097.
   Google Scholar